Outcomes Associated with Warfarin Use in Older Patients with Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings from the ADHERE Registry Linked to Medicare Claims

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2012 Oct 17

PMID 23070696

Citations 10

Authors

Paul L Hess

Melissa A Greiner

Gregg C Fonarow

Winslow Klaskala

Roger M Mills

Soko Setoguchi

Sana M Al-Khatib

Adrian F Hernandez

Lesley H Curtis

Affiliations

Soon will be listed here.

Abstract

Background: Warfarin use and associated outcomes in patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device have not been described previously.

Hypothesis: We hypothesized that warfarin is underused and is associated with lower risks of mortality, thromboembolic events, and myocardial infarction.

Methods: Using data from a clinical registry linked with Medicare claims, we examined warfarin use at discharge and 30-day and 1-year Kaplan-Meier estimates of all-cause mortality and cumulative incidence rates of mortality, thromboembolic events, myocardial infarction, and bleeding events in patients 65 years or older, with a history of atrial fibrillation and a cardiovascular implantable electronic device admitted with heart failure between 2001 and 2006, who were naïve to anticoagulation therapy at admission. We compared outcomes between patients who were or were not prescribed warfarin at discharge and tested associations between treatment and outcomes.

Results: Of 2586 eligible patients in 252 hospitals, 2049 were discharged without a prescription for warfarin. At 1 year, the group discharged without warfarin had a higher mortality rate after discharge (37.4% vs 28.8%; P < 0.001) but similar rates of thromboembolism, myocardial infarction, and bleeding events. After adjustment, treatment with warfarin was associated with lower risk of all-cause death 1 year after discharge (hazard ratio: 0.76, 95% confidence interval: 0.63-0.92).

Conclusions: Among older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device, 4 of 5 were discharged without a prescription for warfarin. Warfarin nonuse was associated with a higher risk of death 1 year after discharge. Clin. Cardiol. 2011 DOI: 10.1002/clc.22064 Damon M. Seils, MA, Duke University, assisted with manuscript preparation. Mr. Seils did not receive compensation for his assistance apart from his employment at the institution where the study was conducted. This study was supported by a research agreement between Duke University and Janssen Pharmaceuticals. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Citing Articles

The imminent epidemic of atrial fibrillation and its concomitant diseases - Myocardial infarction and heart failure - A cause for concern.

Borschel C, Schnabel R Int J Cardiol. 2018; 287:162-173.

PMID: 30528622 PMC: 6524760. DOI: 10.1016/j.ijcard.2018.11.123.

Perioperative management of antithrombotic therapy in patients receiving cardiovascular implantable electronic devices: a network meta-analysis.

He H, Ke B, Li Y, Han F, Li X, Zeng Y J Interv Card Electrophysiol. 2017; 50(1):65-83.

PMID: 28842832 DOI: 10.1007/s10840-017-0280-4.

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.

Violi F, Soliman E, Pignatelli P, Pastori D J Am Heart Assoc. 2016; 5(5).

PMID: 27208001 PMC: 4889200. DOI: 10.1161/JAHA.116.003347.

Antithrombotic therapy and outcomes after ICD implantation in patients with atrial fibrillation and coronary artery disease: an analysis from the National Cardiovascular Data Registry (NCDR)®.

Ghanbari H, Nallamothu B, Wang Y, Curtis J J Am Heart Assoc. 2015; 4(2).

PMID: 25637345 PMC: 4345865. DOI: 10.1161/JAHA.114.001331.

Atrial fibrillation in decompensated heart failure: associated factors and in-hospital outcome.

Mendes F, Atie J, Garcia M, Gripp E, Silvestre de Sousa A, Feijo L Arq Bras Cardiol. 2014; 103(4):315-22.

PMID: 25352505 PMC: 4206362. DOI: 10.5935/abc.20140123.

References

Leckey R, Aguilar E, Phillips S . Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol. 2000; 16(4):481-5. View

Fonarow G, Albert N, Curtis A, Stough W, Gheorghiade M, Heywood J . Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010; 122(6):585-96. DOI: 10.1161/CIRCULATIONAHA.109.934471. View

Rigler S, Ellerbeck E, Whittle J, Mahnken J, Cook-Wiens G, Shireman T . Comparing methods to identify hip fracture in a nursing home population using Medicare claims. Osteoporos Int. 2010; 22(1):57-61. PMC: 2990808. DOI: 10.1007/s00198-010-1264-8. View

Butler J, Arbogast P, Daugherty J, Jain M, Ray W, Griffin M . Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004; 43(11):2036-43. DOI: 10.1016/j.jacc.2004.01.041. View

Olsson L, Swedberg K, Ducharme A, Granger C, Michelson E, McMurray J . Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006; 47(10):1997-2004. DOI: 10.1016/j.jacc.2006.01.060. View

Goldberger Z, Lampert R . Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006; 295(7):809-18. DOI: 10.1001/jama.295.7.809. View

Krumholz H, Parent E, Tu N, Vaccarino V, Wang Y, Radford M . Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157(1):99-104. View

Curtis L, Hammill B, Eisenstein E, Kramer J, Anstrom K . Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007; 45(10 Supl 2):S103-7. DOI: 10.1097/MLR.0b013e31806518ac. View

Adams Jr K, Fonarow G, Emerman C, Lejemtel T, Costanzo M, Abraham W . Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149(2):209-16. DOI: 10.1016/j.ahj.2004.08.005. View

10.

Gorin L, Fauchier L, Nonin E, De Labriolle A, Haguenoer K, Cosnay P . Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost. 2010; 103(4):833-40. DOI: 10.1160/TH09-10-0746. View

11.

. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154(13):1449-57. View

12.

Skanes A, Healey J, Cairns J, Dorian P, Gillis A, McMurtry M . Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012; 28(2):125-36. DOI: 10.1016/j.cjca.2012.01.021. View

13.

Kociol R, Hammill B, Fonarow G, Klaskala W, Mills R, Hernandez A . Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J. 2010; 160(5):885-92. DOI: 10.1016/j.ahj.2010.07.020. View

14.

Olesen J, Torp-Pedersen C, Hansen M, Lip G . The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107(6):1172-9. DOI: 10.1160/TH12-03-0175. View

15.

Smith P, Arnesen H, Holme I . The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990; 323(3):147-52. DOI: 10.1056/NEJM199007193230302. View

16.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

17.

Birman-Deych E, Waterman A, Yan Y, Nilasena D, Radford M, Gage B . Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005; 43(5):480-5. DOI: 10.1097/01.mlr.0000160417.39497.a9. View

18.

Feinberg W, Blackshear J, Laupacis A, Kronmal R, Hart R . Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995; 155(5):469-73. View

19.

Benjamin E, Wolf P, DAgostino R, Silbershatz H, Kannel W, Levy D . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98(10):946-52. DOI: 10.1161/01.cir.98.10.946. View

20.

Ogilvie I, Newton N, Welner S, Cowell W, Lip G . Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123(7):638-645.e4. DOI: 10.1016/j.amjmed.2009.11.025. View